Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 80


European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short version - EDF in cooperation with EADV and IPC.

Nast A, Gisondi P, Ormerod AD, Saiag P, Smith C, Spuls PI, Arenberger P, Bachelez H, Barker J, Dauden E, de Jong EM, Feist E, Jacobs A, Jobling R, Kemény L, Maccarone M, Mrowietz U, Papp KA, Paul C, Reich K, Rosumeck S, Talme T, Thio HB, van de Kerkhof P, Werner RN, Yawalkar N.

J Eur Acad Dermatol Venereol. 2015 Oct 19. doi: 10.1111/jdv.13354. [Epub ahead of print] No abstract available.


Predictors of Topical Use in Psoriasis Patients in the REFINE Study.

Gooderham MJ, Poulin-Costello M, Shelton J, Bayan N, Papp KA.

J Cutan Med Surg. 2015 Sep 1. pii: 1203475415604322. [Epub ahead of print]


Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis.

Menter A, Thaçi D, Papp KA, Wu JJ, Bereswill M, Teixeira HD, Rubant S, Williams DA.

J Am Acad Dermatol. 2015 Sep;73(3):410-9.e6. doi: 10.1016/j.jaad.2015.06.038. Epub 2015 Jul 16.


Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.

Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R; OPT Pivotal 1 and OPT Pivotal 2 investigators.

Br J Dermatol. 2015 Oct;173(4):949-61. doi: 10.1111/bjd.14018.


Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.

Valenzuela F, Papp KA, Pariser D, Tyring SK, Wolk R, Buonanno M, Wang J, Tan H, Valdez H.

BMC Dermatol. 2015 May 8;15:8. doi: 10.1186/s12895-015-0025-y.


Long-term Management of Moderate to Severe Plaque Psoriasis Patients With Etanercept: A Case Series.

Bourcier M, Papp KA, Gulliver WP, Poulin Y, Barber K, Poulin-Costello M, Shelton J.

J Cutan Med Surg. 2015 Nov;19(6):561-9. doi: 10.1177/1203475415584511. Epub 2015 May 7.


Evidence that a neutrophil-keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis.

Reich K, Papp KA, Matheson RT, Tu JH, Bissonnette R, Bourcier M, Gratton D, Kunynetz RA, Poulin Y, Rosoph LA, Stingl G, Bauer WM, Salter JM, Falk TM, Blödorn-Schlicht NA, Hueber W, Sommer U, Schumacher MM, Peters T, Kriehuber E, Lee DM, Wieczorek GA, Kolbinger F, Bleul CC.

Exp Dermatol. 2015 Jul;24(7):529-35. doi: 10.1111/exd.12710. Epub 2015 May 8.


Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE.

Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, Shelton J, Garces K, Toole J, Poulin-Costello M.

J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1555-61. doi: 10.1111/jdv.12934. Epub 2015 Jan 21.


A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients with moderate to severe plaque psoriasis (REFINE).

Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, Shelton J, Toole J, Vieira A, Poulin-Costello M.

J Eur Acad Dermatol Venereol. 2015 Feb;29(2):361-6. doi: 10.1111/jdv.12555. Epub 2014 Jul 1.


Efficacy of tofacitinib, an oral janus kinase inhibitor, on clinical signs of moderate-to-severe plaque psoriasis in different body regions.

Menter A, Papp KA, Tan H, Tyring S, Wolk R, Buonanno M.

J Drugs Dermatol. 2014 Mar;13(3):252-6.


Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against low-risk HPV types (PATRICIA randomized trial): an unexpected observation.

Szarewski A, Skinner SR, Garland SM, Romanowski B, Schwarz TF, Apter D, Chow SN, Paavonen J, Del Rosario-Raymundo MR, Teixeira JC, De Carvalho NS, Castro-Sanchez M, Castellsagué X, Poppe WA, De Sutter P, Huh W, Chatterjee A, Tjalma WA, Ackerman RT, Martens M, Papp KA, Bajo-Arenas J, Harper DM, Torné A, David MP, Struyf F, Lehtinen M, Dubin G.

J Infect Dis. 2013 Nov 1;208(9):1391-6. doi: 10.1093/infdis/jit360.


Immune response to pneumococcus and tetanus toxoid in patients with moderate-to-severe psoriasis following long-term ustekinumab use.

Brodmerkel C, Wadman E, Langley RG, Papp KA, Bourcier M, Poulin Y, Ho V, Guenther L, Kunynetz R, Nigen S, Vender R, Wasel N, Hsu MC, Szapary P.

J Drugs Dermatol. 2013 Oct;12(10):1122-9.


Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics.

Mease PJ, Gladman DD, Papp KA, Khraishi MM, Thaçi D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R, Alvarez D.

J Am Acad Dermatol. 2013 Nov;69(5):729-35. doi: 10.1016/j.jaad.2013.07.023. Epub 2013 Aug 24.


Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.

Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM.

J Eur Acad Dermatol Venereol. 2014 Jun;28(6):790-8. doi: 10.1111/jdv.12177. Epub 2013 May 17.


Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.

Papp KA, Griffiths CE, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, Chan D, Hsu MC, Ho V, Ghislain PD, Strober B, Reich K; PHOENIX 1 Investigators; PHOENIX 2 Investigators; ACCEPT Investigators.

Br J Dermatol. 2013 Apr;168(4):844-54. doi: 10.1111/bjd.12214.


Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study.

Kimball AB, Papp KA, Wasfi Y, Chan D, Bissonnette R, Sofen H, Yeilding N, Li S, Szapary P, Gordon KB; PHOENIX 1 Investigators.

J Eur Acad Dermatol Venereol. 2013 Dec;27(12):1535-45. doi: 10.1111/jdv.12046. Epub 2012 Dec 20.


PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.

Papp KA, Strober B, Augustin M, Calabro S, Londhe A, Chevrier M; PSOLAR investigators and Steering Committee.

J Drugs Dermatol. 2012 Oct;11(10):1210-7.


Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.

Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB.

Br J Dermatol. 2013 Feb;168(2):412-21. doi: 10.1111/bjd.12110. Epub 2013 Jan 18.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk